5 Questions That Need Answers from Novartis


Published on

Novartis (NVS) is one of the planet's biggest drugmakers, but it's facing significant challenges now that Ranbaxy has won FDA approval for its Diovan generic alternative. To blunt the impact of lost sales, Novartis' is orchestrating a restructuring that includes an oncology deal with GlaxoSmithKline and selling its animal health business to Eli Lilly. In the following slideshow, I outline five important questions investors will want answers to during Novartis' second quarter earnings conference call on July 17th.

Published in: Healthcare
1 Comment
1 Like
No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

5 Questions That Need Answers from Novartis

  1. 1. What You Need To Know Ahead of Novartis’ Earnings
  2. 2. Novartis’ overview Novartis is one of the largest global drug manufacturers.  $14 billion in first quarter sales.  50 marketed products across 5 segments:  Pharmaceuticals: $7.8 billion in Q1 sales.  Alcon: An eye care portfolio with $2.6 billion in Q1 sales.  Sandoz: A generics manufacturer with $2.3 billion in Q1 sales.  Vaccines: $215 million in Q1 sales (exiting).  Consumer healthcare: $1 billion in Q1 sales (shifting to a joint venture).
  3. 3. Novartis’ overview Patent risk may weigh down results. 1. Diovan – Sales fell 20% in 2013. – Sales fell 13% year-over-year to $803 million in Q1. – Diovan monotherapy generic entering the U.S. market. • Diovan monotherapy represents 90% of U.S. Diovan sales. 2. Zometa – Sales fell 53% in 2013. – Sales fell 69% to $74 million in Q1.
  4. 4. Revenue risk & opportunity Brand name drugs account for the majority of Novartis’ sales. • Patent threat. • New drug launches/pipeline. Restructuring consolidates focus. Novartis’ sales remain steady despite patent losses last year.
  5. 5. Reasons for sales optimism Fast growing therapies in the first quarter: – Gilenya: An oral treatment for relapsing MS. • Sales up 31% to $552 million in Q1 • Competition this year from Biogen’s Tecfidera and Sanofi’s Aubagio. – Tasigna: A therapy for chronic myeloid leukemia. • Sales up 19% to $337 million in Q1. – Galvus: A diabetes drug sold overseas. • Sales up 15% to $308 million
  6. 6. Reasons for sales optimism Restructuring for growth: •Novartis’ acquires Glaxo’s cancer products. •$1.6 billion in 2013 sales. •Will pay $16 billion to Glaxo. •Novartis’ divests non-flu vaccines. •Receives $5.3 billion from Glaxo. •Creates a consumer health joint venture. •Sells its animal health business. •Receives $5.4 billion from Eli Lilly. •Net cash outflow = $7.6 billion. Pipeline opportunity: 28 phase 3 or pivotal programs. •6 new molecules. •Significant biosimilars program. What to look for in the Q2 report Progress on the restructuring. Updated timing for filings.
  7. 7. Earnings outlook Novartis has a poor track record of out-pacing analyst estimates. Delays in launching a Diovan competitor have analysts boosting their outlook for the quarter over the past 90 days, but the launch of Ranbaxy’s generic has them less optimistic for the year. Enthusiasm for 2015; however, is increasing thanks to the restructuring.
  8. 8. 5 Fool-worthy questions How quickly will Diovan sales fall now that Ranbaxy’s generic has been approved? Are Novartis’ restructuring plans progressing as promised? Any updates to FDA or EU filings for new drugs? Did Gilenya sales continue to grow in the face of rising competition? • Biogen’s Tecfidera launch overseas. • Sanofi’s Aubagio growth is outpacing Gilenya. Any insight into future cash flow? • Historically returns a significant amount of its cash flow to investors. • Currently yields 3%.
  9. 9. .Crush non-dividend paying counterparts over the long term with our free report on top dividend stocks.